A randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase II study to evaluate the efficacy and safety of MABT5102A in patients with mild to moderate alzheimer�s disease

�To evaluate the efficacy of MABT5102A compared with placebo, when administered over 68 weeks to patients with mild to moderate AD, in inhibiting disease progression using the Alzheimer�s Disease Assessment Scale Cognitive Subscale (ADAS-Cog [12-item]) �To evaluate the safety and tolerability of MABT5102A compared with placebo when administered over 68 weeks to patients with mild to moderate AD